Press coverage about Alexion Pharmaceuticals (NASDAQ:ALXN) has trended somewhat positive recently, according to Accern. The research group ranks the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Alexion Pharmaceuticals earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.8285064007301 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:
- Alexion Pharm Up 25.8% Since SmarTrend Uptrend Call (ALXN) (mysmartrend.com)
- ETFs with exposure to Alexion Pharmaceuticals, Inc. : August 15, 2017 (finance.yahoo.com)
- Alexion Receives Three New U.S. Patents for Soliris® (eculizumab), Extending Patent Protection Into 2027 (finance.yahoo.com)
- Alexion Pharmaceuticals : And Sema4 Partner In Rare Disease Diagnostics And Systems Biology (4-traders.com)
- Stock Performance Check on Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) - Jonesboro Recorder (jonesbororecorder.com)
ALXN has been the subject of a number of analyst reports. TheStreet upgraded shares of Alexion Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Friday, July 14th. Stifel Nicolaus restated a “buy” rating and issued a $157.00 price objective on shares of Alexion Pharmaceuticals in a research report on Wednesday, May 24th. Leerink Swann restated a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Tuesday, May 23rd. Deutsche Bank AG cut their price objective on shares of Alexion Pharmaceuticals from $160.00 to $153.00 and set a “buy” rating for the company in a research report on Thursday, May 25th. Finally, Goldman Sachs Group, Inc. (The) restated a “buy” rating and issued a $158.00 price objective on shares of Alexion Pharmaceuticals in a research report on Wednesday, May 24th. Five research analysts have rated the stock with a hold rating, twenty have assigned a buy rating and two have given a strong buy rating to the company’s stock. Alexion Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $156.89.
Shares of Alexion Pharmaceuticals (NASDAQ ALXN) traded up 0.93% on Tuesday, hitting $135.21. 1,033,348 shares of the company traded hands. The stock has a market capitalization of $30.18 billion, a price-to-earnings ratio of 58.63 and a beta of 1.41. The firm’s 50 day moving average price is $129.58 and its 200-day moving average price is $122.87. Alexion Pharmaceuticals has a 1-year low of $96.18 and a 1-year high of $145.41.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.08 by $0.48. The company had revenue of $912 million during the quarter, compared to the consensus estimate of $846.15 million. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. Alexion Pharmaceuticals’s revenue was up 21.1% on a year-over-year basis. During the same period last year, the company earned $1.13 earnings per share. On average, equities research analysts expect that Alexion Pharmaceuticals will post $5.60 earnings per share for the current year.
In other Alexion Pharmaceuticals news, Director Bros. Advisors Lp Baker bought 660,779 shares of Alexion Pharmaceuticals stock in a transaction on Thursday, June 15th. The shares were acquired at an average price of $117.33 per share, for a total transaction of $77,529,200.07. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ann M. Veneman sold 700 shares of the stock in a transaction on Monday, July 31st. The stock was sold at an average price of $137.74, for a total value of $96,418.00. Following the completion of the sale, the director now owns 6,315 shares in the company, valued at approximately $869,828.10. The disclosure for this sale can be found here. Over the last 90 days, insiders purchased 2,019,734 shares of company stock valued at $235,606,846. 4.35% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: This piece was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://stocknewstimes.com/2017/08/15/alexion-pharmaceuticals-alxn-earning-somewhat-positive-press-coverage-analysis-shows.html.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
